Robert Gardiner - CeCors Pres Director

CEOS Stock

USD 0.02 0 12.00%

Insider

Robert Gardiner is Pres Director of CeCors Inc

Phone	888 376 8258
Web	https://www.psykeyworld.com

CeCors Management Efficiency

The company has return on total asset (ROA) of (1.7972) % which means that it has lost $1.7972 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.261) %, meaning that it created substantial loss on money invested by shareholders. CeCors' management efficiency ratios could be used to measure how well CeCors manages its routine affairs as well as how well it operates its assets and liabilities.

Compare CeCors to Peers

Predict price of CeCors

CeCors Inc currently holds 956.88 K in liabilities. CeCors Inc has a current ratio of 0.32, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist CeCors until it has trouble settling it off, either with new capital or with free cash flow. So, CeCors' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CeCors Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CeCors to invest in growth at high rates of return. When we think about CeCors' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Robert MBA	Predictive Oncology	69
	Robert Hayes	Sharps Technology	57
	MScEE MBA	GlucoTrack	70
	Esq CPA	GlucoTrack	59
	MS MBA	Bionano Genomics	N/A
	Raymond Vennare	Predictive Oncology	71
	DSc OD	Predictive Oncology	N/A
	Donna Polizio	Bionano Genomics	N/A
	Helene Klein	Bionano Genomics	N/A
	Alan Blackman	Sharps Technology	75
	BS BSc	Predictive Oncology	73
	Julia Kirshner	Predictive Oncology	N/A
	Steven MD	Sharps Technology	62
	Adam III	Nexgel Inc	47
	Christopher Stewart	Bionano Genomics	54
	Andrew CPA	Sharps Technology	68
	Robert MBA	Bionano Genomics	56
	Mark CPA	Bionano Genomics	N/A
	Erez BenZvi	GlucoTrack	46
	David Stefansky	Nexgel Inc	53
	Mark Oldakowski	Bionano Genomics	50

Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines to improve and optimize life. Psykey, Inc. was founded in 2002 and is based in Toronto, Canada. CECORS INC operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 6 people. CeCors Inc [CEOS] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

	Return On Equity	-7.26
	Return On Asset	-1.8

CeCors Inc Leadership Team

Elected by the shareholders, the CeCors' board of directors comprises two types of representatives: CeCors inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CeCors. The board's role is to monitor CeCors' management team and ensure that shareholders' interests are well served. CeCors' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CeCors' outside directors are responsible for providing unbiased perspectives on the board's policies.

	John Gustin, Head Devel
	Robert Gardiner, Pres Director
	Sukhinder Kalsi, CFO Director
	Jasbir MD, S Treasurer
	James Fiedler, Chairman, CEO and Pres
	Allen MD, VP Director
	Mark Perkell, VP Counsel

CeCors Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CeCors a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-7.26
	Return On Asset	-1.8
	Current Valuation	87.7 K
	Price To Earning	(0.05) X
	EBITDA	(3.72 M)
	Net Income	(9.3 M)
	Cash And Equivalents	57.42 K
	Total Debt	956.88 K
	Current Ratio	0.33 X
	Book Value Per Share	(0.02) X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for CeCors Pink Sheet Analysis

When running CeCors' price analysis, check to measure CeCors' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CeCors is operating at the current time. Most of CeCors' value examination focuses on studying past and present price action to predict the probability of CeCors' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CeCors' price. Additionally, you may evaluate how the addition of CeCors to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC